was read the article
array:25 [ "pii" => "S1578219021002006" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.07.002" "estado" => "S300" "fechaPublicacion" => "2021-09-01" "aid" => "2602" "copyright" => "AEDV" "copyrightAnyo" => "2021" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2021;112:768-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0001731021000971" "issn" => "00017310" "doi" => "10.1016/j.ad.2020.01.012" "estado" => "S300" "fechaPublicacion" => "2021-09-01" "aid" => "2602" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2021;112:768-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICO CLÍNICA</span>" "titulo" => "Ciclosporina: una vieja amiga en el tratamiento de la urticaria crónica espontánea" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "768" "paginaFinal" => "769" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ciclosporin: An Old Ally in the Treatment of Chronic Spontaneous Urticaria" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "B. Pinilla Martín, F. Tous Romero, F.J. Ortiz de Frutos" "autores" => array:3 [ 0 => array:2 [ "nombre" => "B." "apellidos" => "Pinilla Martín" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Tous Romero" ] 2 => array:2 [ "nombre" => "F.J." "apellidos" => "Ortiz de Frutos" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219021002006" "doi" => "10.1016/j.adengl.2021.07.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002006?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021000971?idApp=UINPBA000044" "url" => "/00017310/0000011200000008/v1_202109020526/S0001731021000971/v1_202109020526/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219021002031" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.07.005" "estado" => "S300" "fechaPublicacion" => "2021-09-01" "aid" => "2651" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:770-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Clinical and Ultrasound Features of Dermatofibromas in Pediatric Patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "770" "paginaFinal" => "772" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Caracterización clínico-ecográfica de dermatomiofibromas en edad pediátrica" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1118 "Ancho" => 1500 "Tamanyo" => 226915 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical and ultrasound characteristics.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "H. Álvarez-Garrido, C. Horcajada-Reales, A. Hernández-Nuñez, J. Borbujo" "autores" => array:4 [ 0 => array:2 [ "nombre" => "H." "apellidos" => "Álvarez-Garrido" ] 1 => array:2 [ "nombre" => "C." "apellidos" => "Horcajada-Reales" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Hernández-Nuñez" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Borbujo" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002031?idApp=UINPBA000044" "url" => "/15782190/0000011200000008/v2_202110201006/S1578219021002031/v2_202110201006/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219021001839" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.05.021" "estado" => "S300" "fechaPublicacion" => "2021-09-01" "aid" => "2625" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2021;112:767-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Ulcerative Lupus Erythematosus Profundus in a Patient With Limited Cutaneous Systemic Sclerosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "767" "paginaFinal" => "768" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Lupus eritematoso profundo ulcerativo en un paciente con esclerosis sistémica cutánea limitada" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1127 "Ancho" => 1500 "Tamanyo" => 398502 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Ulcerative lesions on the forehead (A) and scalp (B), along with swollen fingers and nailfold bleeding (C). Histological features showing focal lymphohistiocytic infiltration and hyaline fat necrosis in the lower dermis to the subcutis (D, E). Lymphocytic infiltration was observed in the muscle layers (F). Foam cells were detected in the vessels (G).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "T. Mori, T. Ito, N. Kikuchi, T. Yamamoto" "autores" => array:4 [ 0 => array:2 [ "nombre" => "T." "apellidos" => "Mori" ] 1 => array:2 [ "nombre" => "T." "apellidos" => "Ito" ] 2 => array:2 [ "nombre" => "N." "apellidos" => "Kikuchi" ] 3 => array:2 [ "nombre" => "T." "apellidos" => "Yamamoto" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731021001411" "doi" => "10.1016/j.ad.2019.10.016" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001411?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021001839?idApp=UINPBA000044" "url" => "/15782190/0000011200000008/v2_202110201006/S1578219021001839/v2_202110201006/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Ciclosporin: An Old Ally in the Treatment of Chronic Spontaneous Urticaria" "tieneTextoCompleto" => true "saludo" => "Dear Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "768" "paginaFinal" => "769" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "B. Pinilla Martín, F. Tous Romero, F.J. Ortiz de Frutos" "autores" => array:3 [ 0 => array:4 [ "nombre" => "B." "apellidos" => "Pinilla Martín" "email" => array:1 [ 0 => "belenpinillamartin@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Tous Romero" ] 2 => array:2 [ "nombre" => "F.J." "apellidos" => "Ortiz de Frutos" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Ciclosporina: una vieja amiga en el tratamiento de la urticaria crónica espontánea" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Since the introduction of omalizumab for the treatment of chronic spontaneous urticaria (CSU), it has been possible to control the disease in a high percentage of patients who had been refractory to treatment with high doses of antihistamines<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a>. According to the most recent European guidelines<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a>, treatment with ciclosporin is indicated in cases where omalizumab has already failed. In this indication, it is prescribed off-label, although it has traditionally been used for treatment of CSU<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a>. Published data are scarce, and only 2 randomized clinical trials involving no more than 16 weeks<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> and 8 weeks<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> of treatment have been performed. Nevertheless, there are cohorts and case series of patients treated with this drug at low doses for longer periods (i.e., up to 10 years)<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a>. We performed the present study to improve our knowledge of ciclosporin for treatment of CSU in patients whose therapy with omalizumab had already failed.</p><p id="par0010" class="elsevierStylePara elsevierViewall">We designed an observational, longitudinal, prospective study of patients diagnosed with CSU and treated with ciclosporin at our center. Previous treatment with omalizumab had failed. We recorded epidemiological and clinical data and assessed the severity of urticaria using the 7-day Urticaria Activity Score (UAS7d). We also recorded the dose of ciclosporin at different points during treatment (baseline, maximum dose, end of treatment), duration of treatment and follow-up, and adverse effects observed.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Of a total of 38 patients who had received treatment with omalizumab, 3 (7.9%) did not respond to the biologic and were switched to ciclosporin (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). The UAS7d score at initiation of treatment with ciclosporin was 24, 41, and 42. Ciclosporin was started at 3.8, 3.15, and 3.85 mg/kg/d, respectively. The disease was controlled (UAS7d < 7) in all 3 patients at the first month of treatment, thus making it possible to gradually taper the dose of ciclosporin without flare-ups before suspending it altogether after 5, 14, and 12 months, with doses ranging from 0.46 and 0.68 mg/kg/d. We recorded no recurrences of urticaria in any of the patients. Similarly, no relevant adverse effects were reported during follow-up.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">While ciclosporin has traditionally been used for treatment of CSU, no definitive regimens have been established. A meta-analysis published in 2017<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> analyzed various studies from the literature, including 2 clinical trials<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a>. The results indicate that ciclosporin is an effective treatment for CSU, although they are difficult to extrapolate to real life, since candidates for this approach have long-standing CSU that does not respond to omalizumab and often requires cycles of oral corticosteroids. We must go back to articles published before approval of omalizumab if we are to find regimens for affected patients in the medium term, without inducing the feared adverse effects of ciclosporin. Kessel and Toubi<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> performed a prospective study of 20 patients with CSU that could not be controlled with ciclosporin at 3 mg/kg/d for 3 months who received the drug at 1-2 mg/kg/d continuously until control was achieved. In 8 cases, the drug could be discontinued after 8-14 months of treatment; the remaining 12 patients continued to receive ciclosporin for 60-120 months without adverse effects.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Boubouka et al.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> reported similar results from their prospective study, in which a cohort of 30 patients with CSU received treatment with ciclosporin at doses ranging from 1.5 to 2.5 mg/kg/d depending on symptoms for 5 months. The disease was controlled in 88% of cases with a final dose of 0.55 mg/kg/d.</p><p id="par0030" class="elsevierStylePara elsevierViewall">Our experience indicates that ciclosporin is an option for treating CSU after failure of omalizumab. In our opinion, the most appropriate regimen (i.e., fewer adverse effects with the same efficacy) is an initial dose of 3-4 mg/kg/d until the disease is controlled, followed by gradual tapering to very low doses (<1 mg/kg/d).</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Pinilla Martín B, Tous Romero F, Ortiz de Frutos FJ. Ciclosporina: una vieja amiga en el tratamiento de la urticaria crónica espontánea. Actas Dermosifiliogr. 2021. <span class="elsevierStyleInterRef" id="intr0005" href="https://doi.org/10.1016/j.ad.2020.01.012">https://doi.org/10.1016/j.ad.2020.01.012</span></p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Sex \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Age at onset, y \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Baseline UAS24 h \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Baseline UAS7 d \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Baseline dose, mg/kg \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">UAS24 h at 1 mo \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">UAS7d at 1 mo \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Final dose \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Duration of treatment, mo \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Duration of follow-up, mo \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patient 1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.85 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.68 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patient 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">44 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">41 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patient 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">60 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2723530.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Results From Our Series</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:8 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “Real-world” evidence" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.D. Tharp" 1 => "J.A. Bernstein" 2 => "A. Kavati" 3 => "B. Ortiz" 4 => "K. MacDonald" 5 => "K. Denhaerynck" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamadermatol.2018.3447" "Revista" => array:5 [ "tituloSerie" => "JAMA Dermatol." "fecha" => "2019" "volumen" => "155" "paginaInicial" => "29" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30427977" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticarial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Zuberbier" 1 => "W. Aberer" 2 => "R. Asero" 3 => "A.H. Abdul Latiff" 4 => "D. Baker" 5 => "B. Ballmer-Weber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/all.13397" "Revista" => array:6 [ "tituloSerie" => "Allergy." "fecha" => "2018" "volumen" => "73" "paginaInicial" => "1393" "paginaFinal" => "1414" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29336054" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "25 mg/50 mg/100 mg cápsulas blandas EFG [información folleto]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "U.R. Ciclosporina" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2012" "editorial" => "GERMED FARMACÉUTICA, S.L" "editorialLocalizacion" => "Las Matas (Madrid, España)" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "G.A. Vena" 1 => "N. Cassano" 2 => "D. Colombo" 3 => "E. Peruzzi" 4 => "P. Pigatto" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2006.04.078" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2006" "volumen" => "55" "paginaInicial" => "705" "paginaFinal" => "709" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17010756" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.E. Grattan" 1 => "B.F. O’Donnell" 2 => "D.M. Francis" 3 => "N. Niimi" 4 => "R.J. Barlow" 5 => "P.T. Seed" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1046/j.1365-2133.2000.03664.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2000" "volumen" => "143" "paginaInicial" => "365" "paginaFinal" => "372" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10951147" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclosporine-A in severe chronic urticaria: the option for long-term therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Kessel" 1 => "E. Toubi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2010.02419.x" "Revista" => array:6 [ "tituloSerie" => "Allergy." "fecha" => "2010" "volumen" => "65" "paginaInicial" => "1478" "paginaFinal" => "1482" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20626384" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Kulthanan" 1 => "P. Chaweekulrat" 2 => "C. Komoltri" 3 => "S. Hunnangkul" 4 => "P. Tuchinda" 5 => "L. Chularojanamontri" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaip.2017.07.017" "Revista" => array:5 [ "tituloSerie" => "J Allergy Clin Inmunol Pract." "fecha" => "2017" "volumen" => "6" "paginaInicial" => "586" "paginaFinal" => "599" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of autoinmune uricaria with low-dose cyclosporin a: a one-year follow-up" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Boubouka" 1 => "C. Harissi" 2 => "D. Kouimintzis" 3 => "D. Kalogeromitros" 4 => "P. Stavropoulos" 5 => "A. Katsarou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2340/00015555-0939" "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol." "fecha" => "2011" "volumen" => "91" "paginaInicial" => "50" "paginaFinal" => "54" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21264453" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011200000008/v2_202110201006/S1578219021002006/v2_202110201006/en/main.assets" "Apartado" => array:4 [ "identificador" => "6157" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case and Research Letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011200000008/v2_202110201006/S1578219021002006/v2_202110201006/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002006?idApp=UINPBA000044" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 8 | 12 | 20 |
2024 October | 81 | 40 | 121 |
2024 September | 83 | 25 | 108 |
2024 August | 113 | 65 | 178 |
2024 July | 76 | 26 | 102 |
2024 June | 93 | 29 | 122 |
2024 May | 81 | 30 | 111 |
2024 April | 78 | 29 | 107 |
2024 March | 102 | 25 | 127 |
2024 February | 78 | 28 | 106 |
2024 January | 76 | 30 | 106 |
2023 December | 47 | 20 | 67 |
2023 November | 90 | 31 | 121 |
2023 October | 99 | 25 | 124 |
2023 September | 69 | 35 | 104 |
2023 August | 33 | 7 | 40 |
2023 July | 53 | 35 | 88 |
2023 June | 58 | 26 | 84 |
2023 May | 54 | 27 | 81 |
2023 April | 29 | 23 | 52 |
2023 March | 44 | 36 | 80 |
2023 February | 51 | 20 | 71 |
2023 January | 33 | 24 | 57 |
2022 December | 39 | 38 | 77 |
2022 November | 32 | 23 | 55 |
2022 October | 30 | 27 | 57 |
2022 September | 28 | 28 | 56 |
2022 August | 24 | 37 | 61 |
2022 July | 26 | 39 | 65 |
2022 June | 26 | 21 | 47 |
2022 May | 41 | 41 | 82 |
2022 April | 60 | 38 | 98 |
2022 March | 64 | 65 | 129 |
2022 February | 70 | 40 | 110 |
2022 January | 82 | 43 | 125 |
2021 December | 77 | 42 | 119 |
2021 November | 65 | 47 | 112 |
2021 October | 75 | 68 | 143 |
2021 September | 89 | 61 | 150 |
2021 August | 66 | 50 | 116 |
2021 July | 60 | 37 | 97 |